The vascular effects of cilostazol.
Cilostazol is a phosphodiesterase III inhibitor with pharmacological effects that include vasodilation, inhibition of platelet activation and aggregation, inhibition of thrombosis, increased blood flow to the limbs, improvement in serum lipids with lowering of triglycerides and elevation of high density lipoprotein cholesterol, and inhibition of vascular smooth muscle cell growth. Cilostazol has been shown in multiple randomized clinical trials to result in decreased claudication and improved ability to walk in patients with peripheral arterial disease. In addition, cilostazol has been shown in multiple randomized clinical trials to decrease restenosis in the setting of coronary stent implantation. The purpose of the present paper was to review the vascular effects of cilostazol and to present results of the major clinical trials of the use of cilostazol in peripheral arterial disease and percutaneous coronary intervention with stent implantation.
Emory Center for Outcomes Research, Emory University, Atlanta, Georgia 30322, USA. wweintr@emory.edu
William S
WS
Weintraub
D000818:Animals; D049109:Cell Proliferation / Q000187:drug effects; D000077407:Cilostazol; D023903:Coronary Restenosis / Q000517:prevention & control; D004730:Endothelium, Vascular / Q000187:drug effects*; D006801:Humans; D008055:Lipids / Q000097:blood; D016491:Peripheral Vascular Diseases / Q000188:drug therapy; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D013777:Tetrazoles / Q000494:pharmacology* / Q000627:therapeutic use*; D017539:Tunica Intima / Q000166:cytology / Q000187:drug effects
D008055:Lipids; D010726:Phosphodiesterase Inhibitors; D010975:Platelet Aggregation Inhibitors; D013777:Tetrazoles; D000077407:Cilostazol